← Map · Health Care Equipment · S&P 500
RVTY REVVITY $16.2B
Close, not the door. Signals AI is the software offer, not the whole company.
8 of 15
Reach, Weight, and Proof.
What they are doing
Revvity is diagnostics plus a software business. The software piece now has a named product: Signals AI, built into Signals One, so a scientist can query connected R&D data in plain language. A July connector lets that same data be used from Claude. A January deal puts Lilly prediction models on the Signals Xynthetica platform. Diagnostics, which drove the quarter, is not described as an AI result. This is one business inside the company, live, with no attach number.
Why the score
- Reach 2 not 3: the AI work is in Signals software. It has not shown up in diagnostics.
- Weight 3 not 2: Signals AI is in the software offer. A rival does not get this by buying generic seats.
- Weight 3 not 4: it is not how Revvity as a whole goes to market.
- Proof 3 not 4: the product is launched and named. No share of software revenue, no scientist-usage number.
What would move it next quarter: A number on Signals AI attach, or the same layer showing up in a diagnostic product.
Open these first
Evidence
Built natively into the Signals One platform, Signals AI helps scientists turn connected R&D data into decisions using natural language. Select capabilities are available today. Additional capabilities were still to come.
Scientists can reach Signals AI and connected R&D knowledge through Claude. The connector extends the software. It is not a diagnostic result.
Lilly predictive models are offered through Signals Xynthetica. Revvity and Lilly jointly fund access for selected biotechs. That is distribution of someone else's models inside Revvity software.